SARS-CoV-2 S (RBD) ORF Mammalian 

To Order Contact us: stephen@expresspharmapulse.com

Spike S1 RBD, Fc fusion (SARS-CoV-2)
100699-2 100 µg
EUR 520
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)
100684-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)
100696-2 1 mg
EUR 3200
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)
100938-2 50 µg
EUR 555
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

SARS-CoV-2 (COVID-19) S RBD Recombinant Protein
10-413 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S RBD Recombinant Protein
10-431 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Recombinant Protein RBD
11-215 0.2 mg
EUR 1086
Description: It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S RBD Recombinant Protein
97-093 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag
E80024-2 1 ml
EUR 4995.1

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion
E80026-2 50 ul
EUR 823.9

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)
100698-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)
100769-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)
100846-2 1 mg
EUR 2600
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

SARS-CoV-2 Spike RBD Nanobody
A73680-050 50 ul Ask for price

SARS-CoV-2 Spike RBD Nanobody
A73680-100 100 ul
EUR 882.2

SARS-CoV-2 Spike RBD Nanobody
A73680
  • Ask for price
  • EUR 882.20
  • 50 ul
  • 100 ul

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag
E80027
  • EUR 635.80
  • EUR 4087.60
  • 1 ml
  • 100 ul

3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate
79952-2 10 mg
EUR 3460
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹.

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag
E80023-2 1 ml
EUR 3934.7

Spike S1 RBD, Avi-His-tag, Biotin-labeled (SARS-CoV-2)
100697-2 50 µg
EUR 480
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD, His-Avi-Tag, Biotin-Labeled (SARS-CoV-2)
100937-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This construct contains a C-terminal His-tag (6xHis) followed by an Avi-Tag. The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

Spike RBD (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)
100977-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, originally discovered in the United Kingdom, and contains mutation N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Spike RBD (B.1.351 Variant) Avi-His-Tag (SARS-CoV-2)
100978-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.351, orignally discovered in South Africa and contains mutations K417N, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification and shows less than 5% aggregation in gel filtration. 

SARS-CoV-2 (COVID-19) S Protein RBD Recombinant Protein
10-433 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial
E80028-2 100 ul
EUR 860.2

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag
E80025-2 1 ml
EUR 3934.7

Spike S1 RBD, Fc-Fusion, Avi-Tag, Biotin-labeled (SARS-CoV-2)
100695-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90% MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)
100993-2 1 mg
EUR 2995
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to the RBD of SARS-CoV-2 Variant P.1, originally discovered in Brazil, and contains the three mutations  K417T, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following affinity purification.

Spike S1 RBD (B.1.617 Variant), Avi-His-Tag (SARS-CoV-2)
101156-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally identified in India, and contains mutations L452R and E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

SARS-CoV-2 (COVID-19) S1 RBD Antibody [RBD-2B9]
SD9437-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [RBD-2B9]
SD9437-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S Protein RBD-SD1 Recombinant Protein
92-736 0.05 mg
EUR 468.6
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein RBD-SD1 Recombinant Protein
92-737 0.02 mg
EUR 556.8
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein RBD (N501Y) Recombinant Protein
92-762 0.05 mg
EUR 569.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein RBD (N501Y) Recombinant Protein
92-763 0.05 mg
EUR 569.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

3CL Protease (SARS-CoV-2)
100823-2 500 µg_x000D_
EUR 3360
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa.

Spike (SARS-CoV-2) Lentivirus
78010-2 500 µl x 2
EUR 2095
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag
E80021
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 (COVID-19) RBD Recombinant Protein
10-078 0.1 mg
EUR 619.8
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. _x000D__x000D__x000D_Polyclonal RBD-specific antibodies can block ACE2 binding 10, 11, and anti-RBD neutralizing antibodies are present in the sera of convalescent COVID19 patients 12, identifying the RBD as an attractive candidate for vaccines and therapeutics. In addition, the RBD is poorly conserved, making it a promising antigen for diagnostic tests 13 14. Serologic tests for the RBD are highly sensitive and specific for detecting SARS-CoV-2 antibodies in COVID19 patients 13 15. Furthermore, the levels of anti-RBD antibodies correlated with SARS-CoV-2 neutralizing antibodies, suggesting the RBD could be used to predict an individual's risk of disease 13._x000D_

SARS-CoV-2 (COVID-19) Spike RBD Antibody
9087-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody
9087-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Spike S1 RBD, His-tag (SARS-CoV-2)
100687-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Spike S1 RBD, Fc fusion (SARS-CoV-2)
100699-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag
E80020
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag
E80022
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 S Recombinant Antibody
A73672-050 50 ul Ask for price

SARS-CoV-2 S Recombinant Antibody
A73672-100 100 ul
EUR 518.1

SARS-CoV-2 S Recombinant Antibody
A73672
  • Ask for price
  • EUR 518.10
  • 50 ul
  • 100 ul

Spike S1 RBD (V367F), Avi-His-tag Biotin-labeled (SARS-CoV-2) HiP™
100770-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

PLPro, His-tag (SARS-CoV-2)
100735-2 1 mg
EUR 3000
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa.

NSP10/NSP16 Complex (SARS-CoV-2)
100747-2 1 mg
EUR 2500
Description: Complex of SARS-CoV-2 nonstructural protein 10 (NSP10), GenBank Accession No. YP_009725306.1, a.a. 1-139(full length), with N-terminal FLAG-tag, MW=16 kDa and SARS-CoV-2 nonstructural protein 16 (NSP16), Genbank Accession No. YP_009725311, a.a. 1-298(full length), with N-terminal His-tag, MW=34 kDa, co-expressed in a HEK293 cell expression system.

NSP7, His-tag (SARS-CoV-2)
100829-2 1 mg
EUR 2600
Description: SARS-CoV-2 nonstructural protein 7 (NSP7), Genbank Accession No.: YP_009742614, a.a. 1-84(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 10 kDa.

NSP8, His-tag (SARS-CoV-2)
100830-2 1 mg
EUR 2730
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa.

Anti-Nucleocapsid Antibody (SARS-CoV-2 )
100861-2 100 µg
EUR 420
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Nucleocapsid (N) protein.

ORF9b, GST-Tag (SARS-CoV-2)
100962-2 1 mg
EUR 2720
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification.

Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag (SARS-CoV-2) HiP™
101153-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein
10-100 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein
10-117 0.1 mg
EUR 752.1
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein
10-204 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein
10-206 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein
10-303 0.1 mg
EUR 632.4
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein
10-008 0.1 mg
EUR 714.3
Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus.

SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein
10-015 0.1 mg
EUR 714.3
Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus.

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)
9087-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)
9087-biotin-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 Spike RBD protein antibody pair 1
CSB-EAP33245 1 pair
EUR 900
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA.

SARS-CoV-2 (COVID-19) S1 RBD Detection Set
SD9400 1 Set
EUR 569.4
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)
100684-1 20 µg
EUR 295
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)
100696-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)
100938-1 20 µg
EUR 420
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)
100938-3 100 µg
EUR 740
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike S1, Fc fusion (SARS-CoV-2)
100688-2 50 µg
EUR 505
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa.

Anti-Spike S1 Antibody (SARS-CoV-2)
100715-2 100 µg
EUR 440
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S2, Fc-Tag (SARS-CoV-2)
100895-2 500 µg_x000D_
EUR 1815
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa.

3CL Protease (SARS-CoV-2) Assay Kit
79955-2 384 rxns.
EUR 1265
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. 3CL inhibitor GC376 is also included as an inhibitor control.

SARS-CoV-2 Spike Glycoprotein Expression (S) Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid)
CVD19-130PA-1 10 µg
EUR 728

SARS-CoV-2 (COVID-19) UK variant (B.1.1.7) S RBD (N501Y) Recombinant Protein
11-064 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) UK variant (B.1.1.7) S RBD (N501Y) Recombinant Protein
11-069 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Biotinylated Spike RBD Recombinant Protein
10-205 0.1 mg
EUR 752.1
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein
10-304 0.1 mg
EUR 632.4
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein

SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein
20-232 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein

Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant
P1530-10 10 µg
EUR 187.2

Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant
P1530-50 50 µg
EUR 709.2

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5]
SD9431-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5]
SD9431-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B7]
SD9433-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B7]
SD9433-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T5P4-A12]
SD9439-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T5P4-A12]
SD9439-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T5P7-G10]
SD9441-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T5P7-G10]
SD9441-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P8-F9]
SD9503-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P8-F9]
SD9503-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P7-G12]
SD9505-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P7-G12]
SD9505-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T4P5-H12]
SD9507-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T4P5-H12]
SD9507-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T3P1-C8]
SD9511-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 RBD Antibody [T3P1-C8]
SD9511-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag
E80024-1 100 ul
EUR 635.8

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion
E80026-1 20 ul
EUR 588.5

Recombinant SARS-CoV-2 Spike RBD Protein with His-Tag
E80000-1 100 ul
EUR 518.1

Recombinant SARS-CoV-2 Spike RBD Protein with mFc Tag
E80011-1 100 ul
EUR 588.5

Recombinant SARS-CoV-2 Spike RBD Protein with His-Tag
E80015-1 100 ul
EUR 695.2

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)
100698-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)
100769-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)
100846-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (G476S), Avi-His-tag (SARS-CoV-2)
100868 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with G476S mutation and with a C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (B.1.1.7; Alpha Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™
100999-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, also known as variant Alpha originally identified in the United Kingdom, and contains mutation N501Y. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™
101154-2 50 µg
EUR 455
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag
E80027-2 100 ul
EUR 4087.6

3CL Protease (Mpro), MBP-tag (SARS-CoV-2)
100707-2 1 mg
EUR 2535
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), with an N-terminal MBP-tag, expressed in an E. coli expression system, MW=77.5 kDa.

Nucleocapsid Protein, Avi-His-tag (SARS-CoV-2)
100778-2 1 mg
EUR 2730
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

3CL Protease, Untagged (SARS-CoV-2) Assay Kit
78042-2 384 rxns.
EUR 1210
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease sactivity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps.

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
79942-2 500 µl x 2
EUR 4405
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
79981-2 500 µl x 2
EUR 5245
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

pPACK-SPIKE B.1.351 RBD Mutations, SARS-CoV-2 "S" Pseudotype - B.1.351 (S. African) Variant - RBD Mutations - Lentivector Packaging Mix
CVD19-580A-1 10 rxn
EUR 677

Spike S1 RBD (B.1.617.2.1, Delta Plus Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™
101182-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains RBD mutations K417N, L452R and T478K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

SARS-CoV-2 S Recombinant Antibody, HRP Conjugated
A73673-050 50 ul
EUR 377.3

SARS-CoV-2 S Recombinant Antibody, HRP Conjugated
A73673-100 100 ul
EUR 518.1

SARS-CoV-2 S Recombinant Antibody, FITC Conjugated
A73674-050 50 ul
EUR 377.3

SARS-CoV-2 S (RBD) ORF Mammalian